Alltracel Pharmaceuticals today reported positive results from pre-clinical trials on its bio-active technology, and said it is in talks with potential development partners from the pharmaceutical and functional foods industries.
The company said laboratory trials showed its bio-active product in combination with a commercially available statin drug demonstrated "significant" complementary cardiovascular health benefits.
It said the combination decreased the potential for atherosclerosis - clogging of the arteries - significantly more than either product did individually. And it said there was a "significant" reduction of inflammation in the Alltracel bio-active group, potentially reducing arterial plaque build up and decreasing atherosclerosis risk.
Chief executive Tony Richardson said combination trials are currently underway in partnership with a number of existing functional food companies with results scheduled later this quarter.
"This trial's successful statin combination finding in particular encourages us to now escalate development partnership discussions with existing pharmaceutical therapy providers," he added.
The company said that development discussions with potential partners in the functional foods and pharmaceutical sectors in the EU, Asia and North America have commenced.